Investors

Since its creation, SeaBeLife has raised €6 million in capital and financing. We are currently closing a €2 million pre-series A round to accelerate SBL03’s entry into clinical phase, before an €8 million series A round to achieve clinical proof-of-concept on our two programs and initiate industrial partnerships.

Each program targets a potential market estimated at over €5 billion, with patents already granted in Europe and the United States.

SeaBeLife has won several competitions, including the i-Nov competition (France 2030) in 2024.